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Context. Primary renal carcinoid tumours are rare. Their pathogenesis is unknown and the clinical presentation is similar to other
renal tumours thus posing diagnostic dilemmas for clinicians. Objectives. To review the literature for case reports of primary
renal carcinoids. Methods. Literature was extensively searched for case reports for primary renal carcinoids. Reports of metastatic
carcinoidstothekidneyswereexcluded.Results.Approximatelylessthan90casesofprimarycarcinoidtumoursofthekidneyhave
been reported in the literature. A total of 29 cases of primary renal carcinoids were reviewed. The mean age of presentation was
48 years (range 29–75) with both right kidney (48.3%) and left kidney (44.8%) being equally affected. 28.6% of the cases reviewed
werediagnosedasanincidentalfinding.Themeanfollowuptimewas20monthswith73.1%ofpatientswithoutevidenceofdisease
after surgical treatment (radical or partial nephrectomy). Primary carcinoid tumours of the kidney are often well differentiated
tumours. They are often misdiagnosed because of their rarity and similar presentation with other renal tumours. Conclusions.
Primary carcinoid tumours of the kidney are rare tumours with an indolent course with frequent metastasis. Metastatic work up
and followup is required in their management.
1. Introduction
The histology of carcinoid tumours was first described by
Lubarsch in 1888 [1], while the first case of carcinoid in the
gastrointestinal tract was reported by Oberndorfer in 1907
[2].
Carcinoid tumours are neoplasms with neuroendocrine
differentiation. They are thought to arise from APUD cells
with characteristic secretory granules. Although they have
certain clinicopathological features which are specific to the
o r g a ni nw h i c ht h e ya r i s e ,t h e r ea r es e v e r a lf e a t u r e sc o m m o n
to neuroendocrine tumours (NETs) regardless of the site of
origin in the body [3].
There are various systems of nomenclature in the classi-
fication of NETs which has led to confusing terminologies.
Some of which differ in the use of terminologies and criteria
for staging and grading [4]. Attempts have been made
to ensure a single, uniform, and reproducible system of
nomenclature.Klimstraetal.inareviewofthenomenclature,
staging and grading systems in the pathologic classification
of NETs however suggested that in all the systems a sharp
distinction is made between well differentiated and poorly
differentiated with the latter clearly described as high grade
neuroendocrine cancers [3].
WHO in 2010 classified neuroendocrine neoplasms into
NET-well differentiated grade 1, NET-well differentiated
grade 2, NEC-poorly differentiated grade 3 (small and
large cell type), mixed adenoneuroendocrine carcinoma
(MANEC), hyperplastic and preneoplastic lesions. The first
three however refer to carcinoid neoplasms [5].
N E T so c c u ri nv a r i o u ss i t e so ft h eb o d y ;h o w e v e r ,t h e
gastrointestinaltractaccountsfor73.7%whiletherespiratory
tract accounts for 25.1% of carcinoid tumours [6]. They
are known to occur rarely in the genitourinary system. In
males, of all genitourinary carcinoids reported, the testis and
prostate account for 55% and 15%, respectively, while the
kidney and bladder account for 19% and 9%, respectively [7].
This paper seeks to review the literature for primary
carcinoid tumours of the kidney because they are very rare,2 Advances in Urology
oftenmistakenforotherrenaltumours,thehistopathogenesis
are uncertain, and much is not known about them.
2. Methods
The literature was searched extensively for primary carcinoid
tumour of the kidneys using Medline and Ovid SP databases.
Romero et al. [7] in their review of primary renal carcinoid
tumours till 2006 documented 56 cases. The inclusion cri-
teria for our review were relevant publications of primary
carcinoid tumour of the kidney after the published reports
by Romero et al. till date.
Carcinoid tumours of the kidney secondary to metastasis
from other sites were excluded. All studies were assessed
for epidemiological, histological, clinical, diagnostic, ther-
apeutic, and prognostic data. The search terms used were
primary renal carcinoid tumours, neuroendocrine tumours
of the kidney, primary tumours of the kidney, and so forth.
Further publications were identified by manually searching
the references of relevant research papers.
3. Results
The clinical and pathologic data of the 29 cases reviewed and
their clinical outcome are shown in Table 1.
4. Discussion
Primary NETs of the kidney are very rare. Fourty six years
after the first case was reported in 1966 by Resnick et al. [33]
to the best knowledge of the authors approximately less than
9 0c a s e sh a v eb e e nr e p o r t e di nt h el i t e r a t u r e .
4.1. Epidemiology. Individuals between the ages of 13 and 79
years have been known to present with carcinoid tumour of
the kidney [34]. The fifth and sixth decades of life are the
peak age of incidence [7]. The mean age of presentation in
our review was 48 years (range 29–75).
Romero et al. in an analysis of 56 cases of primary
carcinoid tumours of the kidneys reported that the right
k i d n e yw a sm o r ei n v o l v e dt h a nt h el e ft( 6 0 . 9 %v e r s u s3 9 . 1 % )
[7].Ourreviewhoweverdemonstratesequalaffectationofthe
both right (48.3%) and left kidney (44.8%). This agrees with
the findings of Krishnan et al. who reported that both right
and left kidneys are equally affected [34].
Thefemalesex(62%)wasmoreaffectedthanthemalesex
in our review. This is in contrast to the findings of Romero et
al. which suggested that there is no sex predilection; however
carcinoid tumours associated with horseshoe kidneys tend
to have a male sex predilection (1.5:1) which could partly
be explained to be due to the higher incidence of horseshoe
kidneys in men [7, 35]. Familial predisposition has not been
reported [36].
4.2. Pathogenesis. Intrinsic NE cells in normal kidneys have
notbeenreported,andthepathogenesisofprimarycarcinoid
tumour of the kidney is uncertain and remains largely
unknown[34].NEcellshavebeenobservedintheurothelium
of the upper urinary tract [37–39].
Several theories regarding the origins of carcinoid
tumours have been postulated. The first theory suggests ori-
gin from an intrinsic neuroendocrinecell either representing
aminuteendocrine-paracrinecellcomponentoramisplaced
or entrapped progenitor cell (neural crest) of the dispersed
neuroendocrine system during embryogenesis [39]. Guy et
al. in the immunohistochemical study of foetal, infantile,
and adult kidneys concluded that no neuroendocrine cell
was identified in the renal parenchyma thus invalidating
the theory of intrinsic NE cells in the pathogenesis of renal
carcinoid tumour [39].
ThetheoryofderivationfrominterspersedNEcellsdueto
intestinalmetaplasiaofthepyelocalycealurotheliuminduced
by chronic infection or inflammation has been considered
[34]. Romero et al. noted that intestinal metaplasia have not
b e e nf r e q u e n t l yr e p o r t e di nt h e s et u m o u r sa n dt h e r ea r en o
evidence to suggest chronic pyelonephritis or infection [7].
Metastasis from unknown primary tumours to the kidneys is
another plausible hypothesis [7].
The theory of stem cell neuroendocrine modulation
through neoplastic activation of gene sequences common
to neuroendocrine programmed cells or primitive multi-
potential cell lines that differentiate in a NE direction has
been postulated [36, 37, 39, 40]. El-Naggar et al. noted
loss of heterozygosity at 1 locus on chromosome 3p21. They
concluded that 3p aberrations may constitute a predifferen-
tiation tumour inducing event in the development of renal
neoplasms including renal carcinoids [37].
4.3. Associated Pathologies. Primary renal carcinoids are
k n o w nt ob ea s s o c i a t e dw i t hs o m eo t h e rr e n a lp a t h o l o g i e s .
In a previous review of 56 cases, renal carcinoids were
associatedwithhorseshoekidneys(17.8%),teratomas(14.3%),
and polycystic kidney disease (1.8%) [7]. Our review demon-
strates associations with horseshoe kidneys (25%), one case
of teratoma and one case of mature teratoma coexisting with
primary renal carcinoid tumour in a horseshoe kidney.
H o r s e s h o ek i d n e y sa r ea s s o c i a t e dw i t hi n c r e a s e dr i s ko f
W i l m st u m o u r ,n e o p l a s m so ft h er e n a lp e l v i sa n dc a r c i n o i d
tumours of the kidney [34]. The relative risk of carcinoid
tumours in individuals with horseshoe kidneys compared
to individuals with normal kidneys ranges from 62 to 120
[34, 41, 42]. There are 8 cases of primary renal carcinoid
tumour associated with horseshoe kidneys in our review
[10, 13, 18, 26, 27, 29].
The reported frequent occurrence of renal carcinoids
in the isthmus of the horseshoe kidneys lends credence to
the notion that teratogenic events related to the abnormal
migration of posterior nephrogenic cells in utero may play
a role in the pathogenesis [34]. A case of synchronous
adenocarcinoma and primary renal carcinoid tumour arising
within a teratoma in a horseshoe kidney has been reported
[10].
Teratomas occurring as primary renal tumours are quite
rare. Teratomas have been reported to arise in association
with primary renal carcinoid [12, 43–46]. It is howeverAdvances in Urology 3
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believed that the carcinoid tumours in these teratomas are
derivedfromneuroendocrinecellswhicharisefromgastroin-
testinal or respiratory teratoid epithelial cellular components
[44].Casesofprimaryrenalcarcinoidsarisingwithinmature
teratoma in horseshoe kidneys have also been reported [47,
48].
Other associated pathologies include polycystic kidney
disease. Primary renal carcinoid tumour was first reported
by Shibata et al. [49] as an incidental finding in a lady with
autosomal dominant adult polycystic kidney disease who
underwentbilateralnephrectomybecauseofinfectionsofher
polycystic kidney. Mutations in PKD1 and PKD2 genes are
responsible for the development of polycystic kidney disease.
Thepossibilityofthesemutationsisbelievedtobelowinrenal
carcinoid tumours and the risk of development of primary
carcinoid tumour in people with polycystic kidney disease is
believed to be very low [49].
4.4.ClinicalPresentation. Thediagnosisofprimarycarcinoid
tumour of the kidney has been reported to be incidental
in 25–30% of cases [50] .Th i si ss i m i l a rt ot h efi n d i n g so f
this review with primary carcinoid tumour of the kidney
diagnosed as an incidental finding in 28.6% of cases [13,
18, 20, 23, 32]. The clinical presentation is similar to other
renal neoplasms. The most commonly reported presenting
complaintwasabdominalorflankpain[9,10,12,15–17,19,21,
22,26–30].Othersymptomsincludehaematuria[8,11,18,24]
constipation, urinary frequency, fever, epigastric discomfort,
weight loss, and abdominal mass [17, 19, 24, 25, 27, 28, 30, 31]
which is similar to other research findings [36, 51–53].
Small lesions do complicate the diagnosis of renal car-
cinoid tumours as neither magnetic resonance imaging or
computedtomographyreliablydistinguishesthemfromrenal
cellcarcinoma[7].Misdiagnosisofrenalcarcinoidtumouras
RCC or Wilms tumour has been reported in approximately
15% of cases in the literature [38]. The clinical course of renal
carcinoid is difficult to predict because of the rarity of the
condition; however, it is largely believed to have an indolent
course [54].
NETs of the kidney are capable of producing several
hormones; however, the associations with neuroendocrine
syndromesarenotablyrare[36].NEsyndromeslikecarcinoid
syndrome, Cushing syndrome, Verner Morrison have been
reported to occur in approximately 12.7% of patients with
renal carcinoids [7, 55, 56].
4.5.Imaging. Ultrasoundfindingsinrenalcarcinoidtumours
a sr e p o r t e db yK i me ta l .w h i c ha r ec o n s i s t e n tw i t hp r e v i o u s
reports demonstrate a hyper echoic mass with an incomplete
hypo echoic or anechoic thin rim or halo and central or
peripheral calcifications [44, 45, 51, 57, 58]. The most com-
monimagingfea tur eofallcar cinoidstumoursiscalcifica tion
which is observed in 26.5% of primary renal carcinoids [7].
Centralhypoechoicareasmaysuggestthepresenceofcentral
necrosis [57].
Theultrasoundfindingsaloneposeadiagnosticdilemma
because the findings in primary renal carcinoid tumour with
or without teratoma are similar to findings in small renal cell
Figure1:Demonstratingawellcircumscribedtumourinthekidney.
Reprintedfrom[19]withpermissionoftheEditor-in-ChiefofSaudi
Journal of Kidney Diseases and Transplant on behalf of the editorial
board.
carcinoma. They however differ from the findings in large
renal cell carcinoma [45].
Computed tomography findings may be heterogeneous
demonstrating minimal contrast enhancement. It may also
demonstrateawell-circumscribedenhancedornonenhanced
mass (Figure 1). The mass may be solid or with a cystic
component with calcification in some patients [36, 44, 52, 53,
57].Renalcarcinoidshaveacharacteristictendencytoappear
wi thminimalo rpoo renhancemen to fco n trastenhancedCT
corresponding to the hypovascular or avascular lesions on
angiography [36, 44, 52, 57].
Somatostatin receptor scintigraphy (SRS) is useful for
diagnosis, staging, and monitoring after treatment for
the development of recurrence or metastasis of carcinoid
tumours. Radiolabeled octreotide is a somatostatin analogue
that has a high affinity for somatostatin receptors. Primary
carcinoids and metastatic lesions do have high affinity recep-
tors for somatostatin in 87% of cases [59–61].
A study suggested that SRS is more sensitive, more
specific, and more accurate than chromogranin A (CgA)
levels (a recognized marker for carcinoid tumours) for
metastatic evaluation of carcinoid tumours. Correlation of
SRSwithotherimagingstudiesandclinicalfollowupfindings
revealed a sensitivity, a specificity, and an accuracy of 82.9%,
97.7%, and 88.0%, respectively. Positive SRS correlated with
elevation of serum CgA levels and both SRS and CgA should
beconsideredtobeusefultoolsintheevaluationofmetastasis
[62].
This is consistent with the findings of Mufarrij et al.
who reported a case of a 40-year-old woman with primary
renal carcinoid tumour with metastasis to the liver which
was missed by CT scan and MRI scan was inconclusive.
Four foci of increased radiotracer activity were identified by
SRS [63]. Another case that highlights the importance of
S R Sw a st h er e p o r t e dc a s eo fa6 7 - y e a r - o l dl a d yw h oh a da
rightnephrectomyandretroperitoneallymphadenectomyfor
suspected RCC which however turned out to be a carcinoid
on further histology review. All imaging modalities failed to
detect evidence of disease. SRS however detected SR positive
tissue in the renal bed which was representative of residual
carcinoid tumour [59].6 Advances in Urology
Figure 2: Macroscopic examination shows a well circumscribed
renal tumour mass. Reprinted from [19] with permission of the
Editor-in-Chief of Saudi Journal of Kidney Diseases and Transplant
on behalf of the editorial board.
It is important to note that the drawback for SRS is
that normal renal uptake of the tracer material used in the
evaluation of a primary renal carcinoid may obscure some
lesions [7].
A comparative study of CT scans and SRS as imaging
modalities for NETs concluded that both techniques are
complementary,moreimportantlyinpatientswithmetastatic
disease, inconclusive CT lesions or strong clinical or bio-
chemical evidence of NET with negative scans [64].
4.6. Macroscopic Features. The size of primary carcinoid
t u m o u r so ft h ek i d n e yi no u rr e v i e wr a n g e sf r o m2t o1 6c m .
P r evio usfindin gss ugg es tara n g efr o m1.5t o30cm[7].These
neoplasms with indolent course are usually diagnosed at a
l a r g es i z ew i t ha p p r o x i m a t e l y7 5 %g r e a t e rt h a n4 c m .Th i s
could be due to the vacuous nature of the retroperitoneal
space as kidneys are essentially retroperitoneal organs [7].
Theyarepredominantlysolidmasses(Figure 2)whichare
unilateral and solitary with a third to be partially or wholly
cystic.Theyhavebeenreportedtobewellcircumscribedwith
distinctly lobulated appearance. They exhibit a yellow orange
t or e dt a nc o l o u ro ft h ec u ts u r f a c e s[ 50, 65]. About half are
confined to the kidney, a third involves perirenal fat, and
approximately 10% involve the renal vein [53, 60, 66, 67].
Primary carcinoid tumour of the kidney thrombus
involving the inferior vena cava has been reported [8]. Most
cases arise in the renal parenchyma; however, rare cases aris-
ing from the renal pelvis have been reported [20, 36, 68, 69].
Calcificationofvaryingsizeswhichmaybecentralorperiph-
eral[10–12,16,21–23,25,29,51,58],fociareasofhaemorrhage
[15, 30], necrosis and cystic changes has been documented.
Although cases with necrosis have been previously reported
[69–71] and also observed in our review [8, 15, 17, 26, 28],
n e c r o s i sh a sb e e nr e p o r t e dt ob eu n u s u a l[ 15, 36, 60, 67, 69].
The cystic changes may be uniloculated or multiloculated
[34, 43, 53, 72]. Necrosis and foci areas of haemorrhage
may be associated with neovascularization, rapid tumour
growth, or feeding artery compression [73]. Calcification
could possibly be related to long standing tumour growth
as observed by Hamilton et al. in the case of a 64-year-old
ladywithaprimaryrenaltumourthatpresentedwithwatery-
diarrhoea-hypokalaemia-achlorhydria (WDHA) syndrome
Figure3:Microscopicsectionofthetumourshowingtightlypacked
trabeculae(H&E×250).Reprintedfrom[19]withpermissionofthe
Editor-in-Chief of Saudi Journal of Kidney Diseases and Transplant
on behalf of the editorial board.
[55] .C a l c i fi c a t i o nm a ya l s ob er e l a t e dt ot h ep r e s e n c eo f
coexisting teratoma-like elements [10, 12, 44–46, 48]. Calci-
fication seems to suggest a better prognosis while necrosis
is associated with a higher incidence of metastasis; however,
these relationships are not statistically significant [7].
4.7. Microscopic Features. Carcinoid tumours of the kidney
sharesimilarhistologicalfeaturesascarcinoidtumourinvolv-
ing other sites in the body. They demonstrate distinct demar-
cations from the surrounding renal parenchyma. The most
predominant histological pattern is the trabecular pattern;
however, glandular, solid, nested, insular and mixed patterns
have been reported [7, 36, 50].
The trabecular or ribbon like pattern mixed with nested
pattern with peripheral palisading within the setting of a
highly vascularized yet thin fibro-connective tissue stroma
may be observed. Densely fibrotic or sclerotic stroma may
also be seen [36, 38]. Foci of rosette like structures are
characteristic of carcinoids. Mitotic activity though limited
maybeupto4mitoticfiguresper10highpowerfields(HPF).
Theneoplasticcellsaremonomorphicroundorpolygonal
with granular amphophilic to eosinophilic cytoplasm with
indistinguishable cytoplasmic boundaries. The nuclei are
round to oval, uniform in size, minimally pleomorphic, and
with evenly distributed granular salt and pepper chromatin
(Figure 3). Focal calcification with hyalinization and focal
intraluminal mucin production may be seen [34, 36, 53, 67]
andrarelymetaplasticossificationhasbeenreported[67,69].
Distinct ultra-structural features of renal carcinoids
includeneoplasticcellswithmembraneboundelectrondense
neurosecretory granules ranging in size from 100 to 400nm
usually with a polar distribution. The cells have a swollen
mitochondria with poorly developed rough endoplasmic
reticulum and prominent Golgi complexes [34, 40, 41, 53, 55,
69, 72, 74].
The cell membranes are connected together by small
but well developed desmosomes. Perinuclear aggregates of
intermediatefilamentshavealsobeenreported[7,37,38].The
aggregates of intermediate filaments are thought to represent
abnormal accentuation of the small bundles of filaments
normally present in kulchitsky type cells [75].Advances in Urology 7
Huettner et al. opined that although these histological
featuresaretypicalofcarcinoidtumourandhelpindiagnosis
they however give the tumour a pseudo papillary appearance
[74].
4.8. Immunohistochemical Staining. These tumours have
been reported to be immunoreactive to a variety of neu-
roendocrine markers. The tumours are commonly non-
argentaffin and stains positively for Grimelius’s agyrophil.
They exhibit diffuse immunohistochemical staining for
neuron-specific enolase, prohormone convertase (PC) 1/3
a n dP C2 ,s n a r ep r o t e i nS N A P2 5 ,v e s i c l ea s s o c i a t e dm e m -
brane protein (VAMP), syntaxin, chromogranin (Figure 4),
Leu-7,synaptophysin,andcytokeratins(broad-spectrumand
low-molecular-weight) [34, 36–38, 52, 53, 60, 71, 76].
Serotonin, pancreatic polypeptide, vasoactive intestinal
peptide, and somatostatin staining have been reported in
some cases [34, 35, 37, 52, 53, 69]. Vimentin and S100 protein
staining have been reported to be variable [7, 77]. It is
recommended to perform immunochemistry with several
antibodies when primary renal carcinoid is suspected [78].
Renal carcinoid tumours have demonstrated positivity for
prostaticacidphosphatase;however,prostatespecificantigen
PSA is negative. This lends credence to the theory of a
commonhindgutoriginforthesetumours[37,53,60,77,79].
4.9. Grading. Differentiation suggests the extent to which
neoplastic cells resemble their normal nonneoplastic coun-
terparts while grade refers to the characteristic biological
aggressiveness of the tumour. The WHO and ENETS (Euro-
pean Neuroendocrine Tumour Society) grading systems are
b a s e do nt h ep r o l i f e r a t i v er a t e so ft h et u m o u r s .
The proliferative activity can be assessed by counting
mitoses per unit area of the tumour usually expressed as
m i t o s e sp e r1 0h i g hp o w e rfi e l do ra st h ep e r c e n t a g eo f
immunostaining for the cell cycle-dependent proliferation
marker Ki67 (MIB1) antigen [80–82].
TodeterminetheKi67(MIB1)labelingindex,100tumour
cells have to be assessed in a hot-spot area. In case the
Ki67 positivity is unevenly distributed, several tumour areas
should be evaluated. The ENETS and WHO grading systems
using the Ki67 index and mitotic count are G1 (<2% or <2
mitoses/10HPF), G2 (3–20% or 2–20 mitoses/10HPF), and
G3 (>20% or >20 mitoses/10HPF) [3, 80–82].
4.10. Metastasis. Although primary carcinoid tumour of the
kidney shows a less aggressive course compared to RCC,
metastasisisreportedlyfrequent.Metastaticdiseaseisseenin
50%–60%ofcasesandisusuallydetectedatinitialevaluation
[65]. Our review demonstrates that 44.8% of cases have
metastatic disease.
The rate of metastasis is related to tumour size in renal
carcinoids. Raslan et al. in their review reported that liver
m e t a s t a s i sw a se v i d e n te i t h e ra tp r e s e n t a t i o no rd u r i n gt h e
courseofthedisease.Thehistologicfeaturesofthemetastasis
are similar to those of primary renal tumours [36]. Regional
lymph nodes and the liver are the most frequent sites of
metastasis [34] which is consistent with our review findings.
Figure 4: Diffuse staining of the cytoplasm with chromogranin.
Reprintedfrom[19]withpermissionoftheEditor-in-ChiefofSaudi
Journal of Kidney Diseases and Transplant on behalf of the editorial
board.
Metastasis to other sites like the lungs breast and the thyroid
has been reported [14, 17, 26, 27]. Distant spread has been
reported for up to 7 years after nephrectomy which makes
long-term followup care imperative [7, 36, 44, 70].
4.11. Treatment. Surgical resection of the kidney which may
beopenradicalorpartialnephrectomywithlymphnodedis-
sectionhasbeenvariouslyreportedasthetreatmentofchoice
in the management of localized primary renal carcinoid.
Th ea v e r a g ef o l l o w u pt i m ei no u rr e v i e wi s2 0m o n t h sw i t h
73.1% of patients without evidence of disease after surgical
treatment which suggests that surgical treatment is curative.
Liver metastasis can be treated with open resection or
withminimallyinvasiveablativeprocedures.Metastaticrenal
carcinoid has been noted to be resistant to chemotherapy
[36, 83]. Studies with single agent therapy with 5FU, cisplatin
a n dd o x o r u b i c i nh a v eb e e ns h o w nt oh a v ear e s p o n s er a t e
of approximately 20%, and combination chemotherapy does
not seem to be significantly superior to single agents in the
treatment of metastatic carcinoids [84].
4.12. Therapy with Somatostatin Analogues. Primary carci-
noids and metastatic lesions do have high affinity receptors
for somatostatin in 87% of cases [59–61]. It is also a known
cytostaticagenttoneoplasticcells[82]. Tumour response has
strong correlations to somatostatin receptor expression.
The results of a placebo-controlled randomized double-
blind prospective phase IIIB study on the effect of octreotide
L A Ro nt u m o u rg r o w t hi np a t i e n t sw i t hm e t a s t a t i cm i d g u t
NETS (PROMID Study) suggest that octreotide LAR signif-
icantly lengthens time to tumour progression (14.3 months
in octreotide group versus 6 months in the placebo group)
in patients with functionally active and inactive NETs [85].
There are limited data in the literature regarding the use of
somatostatin analogues in the treatment of primary NETs of
thekidney.Progression-freesurvivalperiodof7monthswith
octreotidetherapycombinedwithpalliativeradiotherapywas
achievedinapatientwithprimaryNEToftheleftkidneywith
metastatic disease. Patient however died within 11 months of
diagnosis [17].8 Advances in Urology
4.13. Targeted Therapy with Sunitinib or Everolimus. NETs
of the gastrointestinal tract just like renal cell carcinoma
have been reported to over express VEGF suggesting a
possible target for antiangiogenic therapy [86]. Sunitinib is a
multitargeted tyrosine kinase inhibitor that inhibits platelet
derived growth factor (PDGF) receptor, VEGF receptor,
and so forth. Everolimus, a more favourable pharmacologic
derivative of rapamycin, inhibits the mammalian target of
rapamycin (mTOR) pathway. mTOR inhibitors which are
termed downstream multisignal inhibitors blocks receptor
tyrosine kinases which are responsible for cell growth and
proliferation, cell motility, and angiogenesis [87].
A phase II trial of everolimus combined with octreotide
LAR in 60 patients with low grade to intermediate-grade
mix of pancreatic (30) lung and gastrointestinal (30) NETs,
demonstrated that everolimus was effective in the treatment
of low grade and intermediate grade NET. 22% (13), 70%
(42), and 22% (5) of patients achieved a partial remission
(PR), stable disease (SD), and disease progression (DP),
respectively [88]. There are limited data on the use of these
novel approaches in the treatment of carcinoid tumours of
the kidney. Sunitinib malate has been reportedly used as an
a d j u v a n tt h e r a p yw i t ht h ep a t i e n td i s e a s ef r e ef o r3 1m o n t h s .
I tm a yb ea r g u e dt h a tt h ep a t i e n tw a sg r o s s l yd i s e a s e - f r e e
following the surgery, and the role of sunitinibas an adjuvant
in this patient remains unknown [16].
4.14. Peptide-Receptor Radionuclide Therapy. Lutetium
DOTATATE alone or in combination with other agents has
been used as a targeted therapy for NETs. Kwekkeboom et
al. in a study of 35 patients with gastro-entero-pancreatic
tumour reported complete remission in one patient (3%),
partial remission in 12 (35%), stable disease in 14 (41%), and
progressive disease in seven, (21%) 3 months after the final
administration of therapy. Tumour response was positively
correlated with a high uptake on the octreoscan and limited
hepatic tumour mass [89] .R e s u l t so fac o n t r o l l e dt r i a lo f5 0
patients with disseminated NETs comparing the outcome
of treatment with combination radioisotopes (
90Y/
177Lu-
DOTATATE) and single radioisotope (
90Y-DOTATATE)
suggest that overall survival was significantly higher in the
combination therapy group (𝑃 < 0.027)[ 90].
Ap h a s eI It r i a lo f
177Lutetium-DOTA-Octreotate ther-
apy in somatostatin receptor-expressing NET is ongoing. 4
(30%) had a partial response to treatment and 9 patients
(70%) exhibited stable disease among the 13 patients who
h a v er e c e i v e dt w oo rm o r ec y c l e so ft h e r a p y .N od i s e a s e
p r o g r e s s i o nw a sn o t e d[ 91].
4.15. Prognosis. The prognosis of renal carcinoids is not
predictable because they exhibit heterogeneous behaviour.
Tumour stage at presentation appears to be the most impor-
tant prognostic factor [36]. Our review showed 73.1% of
patients without evidence of disease after treatment. This
suggests an excellent prognosis.
Tumour size less than 4cm and those confined to the
renal parenchyma show a lower rate of metastasis and
better prognosis. Age older than 40 was also found to have
a significant relationship with advanced stage of disease at
diagnosis and prognosis [7, 36]. Primary carcinoid tumour
of the kidney that developed within the setting of horseshoe
kidneys tends to have a more benign course even in the
presence of lymph node involvement [34, 41, 70].
Theprognosisofprimarycarcinoidtumourofthekidney
arising within a mature teratoma appears good [10]. This
however is in contrast to the findings of Romero et al. that
show that neither horseshoe kidneys nor teratoma derived
carcinoids had a better prognosis compared to primary
carcinoid tumour originating from a normal kidney [7]. The
number of mitoses and degree of cellular atypia appear to
be important histological predictors of prognosis. There is
no clear correlation between the histologic features of the
disease and prognosis and tumour necrosis is not a predictor
of prognosis [36, 44].
G u n e se ta l .r e p o r t e dt h ec a s eo fa6 8 - y e a r - o l dm a l e
p a t i e n tw i t har i g h tr e n a lm a s sl o s tt of o l l o wu pw i t h o u ta n y
medical intervention. Ten years later, the mass had nearly
doubled in size with intrarenal spread, invasion of the pre-
cavalandparaaorticlymphnodeswithoutdistantmetastasis.
Right radical nephrectomy was done and a diagnosis of
primary renal carcinoid tumour was made. This shows that
localized renal carcinoid may remain stable and follow an
indolent course without distant metastasis for as long as 10
years [92].
In conclusion, primary carcinoid tumours of the kidney
are often well differentiated rare tumours with an indolent
course treated with nephrectomy with excellent prognosis.
Th e yo ft e np o s ed i a g n o s t i cd i l e m m a sb e c a u s eo ft h e i rr a r i t y ,
minimal awareness about them, and also because of similar
presentation with other renal tumours which often leads to
infrequent considerations by clinicians.
There is a paucity of data related to the treatment of
primarykidneyNETswithmetastasiswithnovelapproaches.
Metastatic work up must always be done to rule out the
possibility of metastasis from an occult tumour elsewhere
when a clinical diagnosis of renal carcinoid is made. The
use of complimentary imaging techniques including MRI,
CT scan, and SRS must be encouraged. Diagnosis must be
confirmed by the use of immunohistochemical stains. Long-
term followup care is essential because of the prolonged
course of disease despite metastasis.
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